Form 4: Nektar Therapeutics Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Mark Wilson, Chief Legal Officer of Nektar Therapeutics, sold 11,040 shares of common stock to cover tax withholding obligations related to vesting RSUs.
Summary
- On February 19, 2025, Mark Wilson, the Chief Legal Officer of Nektar Therapeutics, sold 11,040 shares of the company's common stock.
- The sale was executed to cover required tax withholding obligations associated with the vesting of restricted stock units (RSUs).
- The shares were sold at a weighted average price of $1.01, with individual transactions ranging from $1.00 to $1.04.
- Following the transaction, Wilson beneficially owns 324,292 shares, including 7,107 shares held in the Issuer's ESPP plan.
Sentiment
Score: 5
Explanation: The document reflects a neutral sentiment as it reports a routine transaction related to tax obligations. It doesn't indicate any significant positive or negative developments for the company.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This sale appears to be routine, covering tax obligations related to equity compensation.
Key Dates
| Date | Description |
|---|---|
| 02/19/2025 | Date of the transaction (sale of shares). |
| 02/21/2025 | Date of signature on the Form 4 filing. |
Keywords
Nektar Therapeutics, NKTR, Form 4, Insider Trading, Mark Wilson, RSUs, Tax Withholding, ESPP, Securities Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.